5.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
AbCellera Biologics shareholders approve director elections and auditor at annual meeting - Investing.com
Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions? - simplywall.st
AbCellera Biologics (ABCL) grants director 111,701 share options - Stock Titan
AbCellera (ABCL) director Stephen Quake awarded 111,701 share options - Stock Titan
AbCellera (ABCL) director receives 111,701 share options grant - Stock Titan
AbCellera (NASDAQ: ABCL) shareholders back directors, auditor and Say-on-Pay - Stock Titan
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - MSN
AbCellera (ABCL) director Sandor Victor reports initial insider status on Form 3 - Stock Titan
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet - MSN
AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell (NASDAQ:ABCL) - Seeking Alpha
Q3 2025 Abcellera Biologics Inc Earnings Call Transcript - GuruFocus
AbCellera Biologics Hits Day Low of $5.50 Amid Price Pressure - Markets Mojo
AbCellera Appoints Dr. Victor Sandor to its Board of Directors - BioSpace
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Progress And Strong Q1 Results - Yahoo Finance
AbCellera’s Shift To Proprietary Drugs Puts ABCL635 And Governance In Focus - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
AbCellera appoints Victor Sandor to board of directors - Investing.com UK
AbCellera appoints Victor Sandor to board of directors By Investing.com - Investing.com South Africa
AbCellera Biologics bets on hot flash antibody as pipeline pivot gains steam - MSN
AbCellera Biologics Adds Victor Sandor to Board - TipRanks
AbCellera appoints Victor Sandor to its Board - TradingView
AbCellera (NASDAQ: ABCL) appoints oncology leader Dr. Victor Sandor as independent director - Stock Titan
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Q1 2026 Abcellera Biologics Inc Earnings Call Transcript - GuruFocus
Abcellera Biologics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam - TradingView
ABCL Stock Jumps As Earnings Beat And Drug Data Fuel Momentum - StocksToTrade
ABCL: Lead antibody for menopausal hot flashes advances to phase II, targeting a $6B market - TradingView
AbCellera (NASDAQ: ABCL) CFO exercises 250,000 share options - Stock Titan
Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model? - simplywall.st
AbCellera Biologics Hits Day High with 12.47% Surge in Stock Price - Markets Mojo
AbCellera Biologics Hits Day High with 7.68% Surge in Stock Price - Markets Mojo
AbCellera Biologics Hits New 52-Week High of $6.79, Up 84% - Markets Mojo
Abcellera Biologics stock hits 52-week high at 6.52 USD By Investing.com - Investing.com India
After golden cross, AbCellera Biologics Inc. (ABCL)'s technical outlook is bright - MSN
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year? - MSN
Abcellera Biologics stock hits 52-week high at 6.52 USD - Investing.com
AbCellera Biologics (NASDAQ:ABCL) Is In A Good Position To Deliver On Growth Plans - Moomoo
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright - Yahoo Finance
ABCL - Finviz
ABCL Technical Analysis & Stock Price Forecast - Intellectia AI
Does AbCellera (ABCL) Have a Clear Path From ABCL635 Data to a Durable Business Model? - Yahoo Finance
AbCellera Biologics Inc. (ABCL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Truist raises AbCellera stock price target on clinical data promise By Investing.com - Investing.com Nigeria
Here’s Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long Term - Insider Monkey
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):